Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × OTHER_GOV × durvalumab × Clear all

Phase

Phase 2 3 Phase 3 1 Phase 1 1

Status

Sponsor Class

OTHER 61 INDUSTRY 45 NIH 4 NETWORK 2 OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Lymphoma, Large B-Cell, Diffuse 1 Lymphoma, Follicular 1

Interventions

fludarabine 5 Nivolumab 5 Cyclophosphamide 5 Radiotherapy 3 Metformin 3 Melphalan 3 Interleukin-2 3 pembrolizumab 2 fludarabine phosphate 2 S 1 (combination) 2 Irinotecan 2 Ipilimumab 2 tremelimumab 1 selinexor 1 olaparib 1 nabiximols 1 ivarmacitinib 1 durvalumab 1 defactinib 1 decitabine and cedazuridine drug combination 1 cedazuridine 1 carfilzomib 1 apatorsen 1 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 1 Topotecan 1 Rituximab 1 Radiosurgery 1 Radiation 1 Pemetrexed 1 Paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03610061 2024-04-12

RaDD

Austin Health

Phase 1 Completed

Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon ⚡